QUANTITATION OF CELL-ASSOCIATED DOXORUBICIN BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AFTER ENZYMATIC DESEQUESTRATION

被引:11
作者
ANDERSEN, A
WARREN, DJ
SLORDAL, L
机构
[1] Department of Clinical Pharmacology, The Norwegian Radium Hospital, Oslo, N-0310, Montebello
关键词
DOXORUBICIN; HPLC; CELLULAR CONCENTRATION;
D O I
10.1007/BF00685077
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A method for measuring cellular concentrations of the anthracycline doxorubicin was developed. The assay involves cell lysis and protein degradation by detergent and proteinase K treatment followed by DNA hydrolysis using DNase I. Prior to high-performance liquid chromatography, samples are deproteinized by the addition of ZnSO4 and methanol. The assay is linear with respect to both the cellular drug content and the number of cells assayed over the ranges tested, and drug recovery is close to 100%. The method has a limit of detection of 50 fmol injected doxorubicin. Within run and between-day coefficients of variation have consistently been found to be in the 5% and 10% range, respectively, in different cell lines exposed to doxorubicin in vitro. The method has been evaluated in analyses of doxorubicin levels in mononuclear blood cells of patients. The assay offers several advantages over commonly used organic extraction techniques and may improve cellular drug monitoring during anthracycline therapy in patients.
引用
收藏
页码:197 / 202
页数:6
相关论文
共 35 条
[1]   PHARMACOKINETICS AND PHARMACODYNAMICS OF LONG-TERM CONTINUOUS-INFUSION DOXORUBICIN [J].
ACKLAND, SP ;
RATAIN, MJ ;
VOGELZANG, NJ ;
CHOI, KE ;
RUANE, M ;
SINKULE, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :340-347
[2]   A SENSITIVE AND SIMPLE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF DOXORUBICIN AND ITS METABOLITES IN PLASMA [J].
ANDERSEN, A ;
WARREN, DJ ;
SLORDAL, L .
THERAPEUTIC DRUG MONITORING, 1993, 15 (05) :455-461
[3]   CELLULAR UPTAKE AND METABOLISM OF DAUNORUBICIN AS DETERMINED BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - APPLICATION TO L1210 CELLS [J].
BAURAIN, R ;
ZENEBERGH, A ;
TROUET, A .
JOURNAL OF CHROMATOGRAPHY, 1978, 157 (SEP) :331-336
[4]   EFFECT OF CELL-DENSITY ON INTRACELLULAR ADRIAMYCIN CONCENTRATION AND CYTO-TOXICITY IN EXPONENTIAL AND PLATEAU PHASE EMT6 CELLS [J].
CHAMBERS, SH ;
BLEEHEN, NM ;
WATSON, JV .
BRITISH JOURNAL OF CANCER, 1984, 49 (03) :301-306
[5]  
CHANG BK, 1989, ANTICANCER RES, V9, P347
[6]   COMPARATIVE CARDIOTOXICITY AND ANTITUMOR-ACTIVITY OF DOXORUBICIN (ADRIAMYCIN) AND 4'-DEOXYDOXORUBICIN AND THE RELATIONSHIP TO INVIVO DISPOSITION AND METABOLISM IN THE TARGET TISSUES [J].
CUMMINGS, J ;
WILLMOTT, N ;
MORE, I ;
KERR, DJ ;
MORRISON, JG ;
KAYE, SB .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (09) :1521-1526
[7]   PHARMACOLOGY OF ADRIAMYCIN - THE MESSAGE TO THE CLINICIAN [J].
CUMMINGS, J ;
SMYTH, JF .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (04) :579-582
[8]   THE MOLECULAR PHARMACOLOGY OF DOXORUBICIN INVIVO [J].
CUMMINGS, J ;
ANDERSON, L ;
WILLMOTT, N ;
SMYTH, JF .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (05) :532-535
[9]   DISPOSITION KINETICS OF ADRIAMYCIN, ADRIAMYCINOL AND THEIR 7-DEOXYAGLYCONES IN AKR MICE BEARING A SUB-CUTANEOUSLY GROWING RIDGWAY OSTEOGENIC-SARCOMA (ROS) [J].
CUMMINGS, J ;
MERRY, S ;
WILLMOTT, N .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (04) :451-460
[10]   KINETICS AND SENSITIVITY OF DAUNORUBICIN IN PATIENTS WITH ACUTE-LEUKEMIA [J].
DEGREGORIO, MW ;
HOLLERAN, WM ;
MACHER, BA ;
LINKER, CA ;
WILBUR, JR .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1984, 13 (03) :230-234